Dynatrace, Inc.

**Signal Note: Eventide Initiates DT Position** Eventide's $340K entry into Dynatrace (software observability platform) represents a modest diversification away from pure-play biotech into enterprise software infrastructure. This move likely reflects portfolio rebalancing rather than a thematic biotech thesis, as DT operates in cloud monitoring—outside Eventide's traditional drug development/healthcare focus.